<DOC>
	<DOCNO>NCT02467244</DOCNO>
	<brief_summary>The aim study evaluate plasma adiponectin level , insulin resistance , cardiovascular risk correlation ( ) patient hypothyroidism also investigate effect levothyroxine parameter . The study may explore lacunae present treatment protocol suggest possibility add-on therapy well management .</brief_summary>
	<brief_title>Effect Levothyroxine Serum Adiponectin , Insulin Resistance Cardiovascular Risk Patients With Hypothyroidism</brief_title>
	<detailed_description>Hypothyroidism associate premature atherosclerosis increase prevalence coronary artery disease . Long-term hypothyroidism associate severe cardiovascular manifestation include reduced intravascular volume , increase systemic vascular resistance , hypertension . Hypothyroidism one main cause secondary dyslipidemia . The classic manifestation hypothyroidism raise VLDL , LDL apo A . The increase cardiovascular risk due dyslipidemia , also hemodynamic change , endothelial dysfunction , hormonal metabolic change . Insulin resistance metabolic syndrome important cardiovascular risk factor insulin-resistant individual raise TSH high LDL concentration . Among various marker associate obesity insulin resistance , particular importance adiponectin inversely related degree adiposity , increase insulin sensitivity , antiatherogenic anti-inflammatory property , hence may cardioprotective . Hypoadiponectinaemia associated obesity , insulin resistance type II diabetes , well atherosclerosis , hypertension coronary artery disease . Treating hypothyroidism levothyroxine antioxidant cholesterol reduce effect , thus already proven beneficial impact cardiovascular function , blood pressure lipid profile . But association adiponectin insulin resistance hypothyroid state future cardiovascular risk still clear publish study domain result study contradictory . The aim study evaluate plasma adiponectin level , insulin resistance , cardiovascular risk correlation ( ) patient hypothyroidism also investigate effect levothyroxine parameter .</detailed_description>
	<mesh_term>Insulin Resistance</mesh_term>
	<mesh_term>Hypothyroidism</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<criteria>Patients either sex , age 18 year suffer hypothyroidism ( hypothyroidism define serum TSH level &gt; 5μIU/ml , serum FT3 level &lt; 1.57 pg/ml , serum FT4 level &lt; 0.7 ng/dL . Subclinical hypothyroidism define elevated TSH level normal serum FT3 FT4 level ) need treatment ( treatment indicate patient TSH level &gt; 10 µIU/mL patient TSH level 5 10 µIU/mL conjunction goiter positive antithyroid peroxidase antibody ( ) . Patients hepatic/renal dysfunction , Diabetes mellitus , chronic inflammatory disease take medication thyroid disease . Euthyroid subject significant medical disease . Patients comorbidites interfere outcome measure . Patients already levothyroxine therapy take medication . Patients subacute thyroiditis exclude study since acute inflammation could influence measurement . Pregnant lactate mother .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Hypothyroidism</keyword>
	<keyword>Serum adiponectin</keyword>
	<keyword>hsCRP</keyword>
	<keyword>Homeostatic Model Assessment ( HOMA-IR )</keyword>
	<keyword>Quantitative Insulin Sensitivity Check Index ( QUICKI )</keyword>
	<keyword>Cardiovascular risk assessment score ( Framingham score )</keyword>
	<keyword>Levothyroxin</keyword>
</DOC>